Anti-cachectic effect of FK317, a novel anti-cancer agent, in colon26 and LX-1 models in mice

The effects of FK317 (11-acetyl-8-carbamoyloxymethyl-4-formyl-6-methoxy-14- oxa-1,11-diazatetra-cyclo[7.4.1.0(2. 7).0(10. 0)]tetradeca-2,4,6-trien-9-yl acetate), a novel anti-cancer agent, on murine adenocarcinoma colon26- and human lung carcinoma LX-1-induced cachexia were investigated in mice. Mice bearing colon26 or LX-1 s.c. lost weight and became cachectic, associated with tumor growth. FK317 and mitomycin C (MMC) inhibited the growth of both tumors. FK317 ameliorated the weight loss induced by the presence of colon 26 or LX-1, while MMC enhanced it. An attenuation of the reduction in the w eights of epididymal fat, gastrocnemius muscle and carcass was observed in FK317-treated tumor-hearing mice in both cachexia models, but not in MMC-tr eated mice. The decreases in the circulating levels of triglyceride, glucos e and non-esterified fatty acid, which were induced by the presence of colo n26, was partially inhibited by treatment with FK317. Overall, this study r evealed that FK317 is a potent anti-cancer drug with anti-cachectic activit y, suggesting that FK317 has potential utility for the treatment of cancer.